Veracyte, Inc.
VCYT
Pozycja w akcjach
#4438
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Cena akcji
$43.58
Kapitalizacja rynkowa
$3.50B
Zmiana (1 dzień)
1.07%
Zmiana (1 rok)
21.63%
Kraj
US
Handel Veracyte, Inc. (VCYT)
Kategoria
Healthcare
EPS dla Veracyte, Inc. (VCYT)
EPS na dzień June 2026 TTM: $1.44
Według najnowszych raportów finansowych i ceny akcji firmy Veracyte, Inc., obecny EPS (TTM) wynosi $1.44. Na koniec roku 2023 firma miała EPS w wysokości $-1.02, wzrost w porównaniu do do EPS z roku 2022, który wynosił $-0.51.
Historia EPS dla Veracyte, Inc. od 2011 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $1.44 | 350.00% |
| 2024 | $0.32 | -131.37% |
| 2023 | $-1.02 | 100.00% |
| 2022 | $-0.51 | -54.05% |
| 2021 | $-1.11 | 68.18% |
| 2020 | $-0.66 | 144.44% |
| 2019 | $-0.27 | -56.45% |
| 2018 | $-0.62 | -31.87% |
| 2017 | $-0.91 | -16.51% |
| 2016 | $-1.09 | -16.15% |
| 2015 | $-1.30 | -4.41% |
| 2014 | $-1.36 | -77.89% |
| 2013 | $-6.15 | 369.47% |
| 2012 | $-1.31 | 28.43% |
| 2011 | $-1.02 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $18.62 | 1,193.06% |
US
|
|
| $5.65 | 292.36% |
US
|
|
| $-1.36 | -194.44% |
US
|
|
| - | - |
CN
|
|
| $5.09 | 253.47% |
US
|
